Tags

Type your tag names separated by a space and hit enter

Plasma somatostatin and plasma glucagon in long-term IDDM without residual B-cell function. No effect of different long-term metabolic control.
Scand J Clin Lab Invest. 1986 Nov; 46(7):635-8.SJ

Abstract

To further study the elevated plasma somatostatin (SRIF)--and reduced plasma glucagon concentrations found in IDDM patients without residual B-cell function compared to normal controls, we investigated 39 such patients, randomly assigned to three different insulin treatment regimens; conventional therapy with two injections a day (CTh), insulin pump (CSII) and multiple injections (MI), for 1 year. They were given an arginine infusion (0.5 g/kg/20 min). The mean basal plasma SRIF values in the CTh, CSII and MI groups were 20.8 +/- 3.3, 18.6 +/- 1.8 and 20.6 +/- 2.8 pmol/l and the mean basal plasma glucagon values were 30 +/- 5.7, 19 +/- 2.3 and 27 +/- 4.7 pmol/l, respectively. Both SRIF and glucagon increased in all groups in relation to arginine infusion. For both hormones, the mean values were highest in the CTh group, lowest in the CSII group, although the differences were not significant. The mean HbA1 values for the last 3 months within the test were 10.0 +/- 0.5, 8.8 +/- 0.3 and 9.1 +/- 0.5%, respectively, in the same order as above. The CTh group had significantly higher HbA1 values than the CSII group (p less than 0.02). We conclude that small differences in long-term blood glucose control are of inconsiderable importance for the islet hormonal response to arginine found in IDDM without B-cell function.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2878490

Citation

Skare, S, et al. "Plasma Somatostatin and Plasma Glucagon in Long-term IDDM Without Residual B-cell Function. No Effect of Different Long-term Metabolic Control." Scandinavian Journal of Clinical and Laboratory Investigation, vol. 46, no. 7, 1986, pp. 635-8.
Skare S, Dahl-Jørgensen K, Kriz V, et al. Plasma somatostatin and plasma glucagon in long-term IDDM without residual B-cell function. No effect of different long-term metabolic control. Scand J Clin Lab Invest. 1986;46(7):635-8.
Skare, S., Dahl-Jørgensen, K., Kriz, V., & Hanssen, K. F. (1986). Plasma somatostatin and plasma glucagon in long-term IDDM without residual B-cell function. No effect of different long-term metabolic control. Scandinavian Journal of Clinical and Laboratory Investigation, 46(7), 635-8.
Skare S, et al. Plasma Somatostatin and Plasma Glucagon in Long-term IDDM Without Residual B-cell Function. No Effect of Different Long-term Metabolic Control. Scand J Clin Lab Invest. 1986;46(7):635-8. PubMed PMID: 2878490.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma somatostatin and plasma glucagon in long-term IDDM without residual B-cell function. No effect of different long-term metabolic control. AU - Skare,S, AU - Dahl-Jørgensen,K, AU - Kriz,V, AU - Hanssen,K F, PY - 1986/11/1/pubmed PY - 1986/11/1/medline PY - 1986/11/1/entrez SP - 635 EP - 8 JF - Scandinavian journal of clinical and laboratory investigation JO - Scand J Clin Lab Invest VL - 46 IS - 7 N2 - To further study the elevated plasma somatostatin (SRIF)--and reduced plasma glucagon concentrations found in IDDM patients without residual B-cell function compared to normal controls, we investigated 39 such patients, randomly assigned to three different insulin treatment regimens; conventional therapy with two injections a day (CTh), insulin pump (CSII) and multiple injections (MI), for 1 year. They were given an arginine infusion (0.5 g/kg/20 min). The mean basal plasma SRIF values in the CTh, CSII and MI groups were 20.8 +/- 3.3, 18.6 +/- 1.8 and 20.6 +/- 2.8 pmol/l and the mean basal plasma glucagon values were 30 +/- 5.7, 19 +/- 2.3 and 27 +/- 4.7 pmol/l, respectively. Both SRIF and glucagon increased in all groups in relation to arginine infusion. For both hormones, the mean values were highest in the CTh group, lowest in the CSII group, although the differences were not significant. The mean HbA1 values for the last 3 months within the test were 10.0 +/- 0.5, 8.8 +/- 0.3 and 9.1 +/- 0.5%, respectively, in the same order as above. The CTh group had significantly higher HbA1 values than the CSII group (p less than 0.02). We conclude that small differences in long-term blood glucose control are of inconsiderable importance for the islet hormonal response to arginine found in IDDM without B-cell function. SN - 0036-5513 UR - https://www.unboundmedicine.com/medline/citation/2878490/Plasma_somatostatin_and_plasma_glucagon_in_long_term_IDDM_without_residual_B_cell_function__No_effect_of_different_long_term_metabolic_control_ DB - PRIME DP - Unbound Medicine ER -